TARPEYO（布地奈德）延迟释放胶囊 - 美国食品和药物管理局（FDA）已批准TARPEYO用于降低成人原发性免疫球蛋白A肾病（IgAN）患者肾功能丧失的风险[1] - TARPEYO是唯一一种经FDA批准的治疗IgAN的药物，可显著减少肾功能丧失[1] NefIgArd临床试验数据 - NefIgArd临床试验数据支持TARPEYO的有效性和安全性[3] - 为成人原发性IgAN患者提供了一种革命性的治疗选择[3]

Exhibit 99.1 INTERIM REPORT JANUARY 1 – JUNE 30, 2023 Filing for full approval of TARPEYO Group Financial Summary Key Figures April 1 - June 30, 2023 ● Net sales amounted to SEK 269.4 million, of which TARPEYO® net sales amounted to SEK 259.2 million, for the three months ended June 30, 2023. For the three months ended June 30, 2022 net sales amounted to SEK 64.0 million, of which TARPEYO net sales amounted to SEK 63.6 million. ● Operating loss amounted to SEK 75.2 million and SEK 209.8 million for the thre ...

Exhibit 99.1 A20N2N2UAL REPORT CACT(9otPfsnr9C....JDB...S....TCL...TI...KT...1NO...TP...OP...2I...IPT.......2SCG..T....BR...TCSI...CSCI..CSF...CSC...CSC...CFS...CCSI...CSCI..CS...CSCSE.PSC...FS...A....CG....D....M....SC...F....G....1TA2hi n n n ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 30, 2022 (Commission File No. 001-39308) CALLIDITAS THERAPEUTICS AB (Translation of registrant's name into English) Kungsbron 1, D5 SE-111 22 Stockholm, Sweden (Address of registrant's principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form ...

Exhibit 99.1 calliditas 2021 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

Calliditas Therapeutics AB (NASDAQ:CALT) Q1 2021 Earnings Conference Call May 18, 2021 8:30 AM ET Company Participants Renée Lucander - CEO Richard Philipson - Chief Medical Officer Fredrik Johansson - CFO Andrew Udell - President, North America Conference Call Participants Yigal Nochomovitz - Citigroup Maury Raycroft - Jefferies Edwin Zhang - H.C. Wainwright Nicholas Rubino - Stifel Rami Katkhuda - LifeSci Capital Operator Ladies and gentlemen, welcome to the Calliditas Therapeutics Q1 2021 Conference. [Op ...

Q1 2021 REPORT May 18, 2021 Disclaimers Important information This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the regulatory pathway for Nefecon, plans for submissions for marketing approvals, plans and strategies for commercialization of Nefecon, if approved, the conduct of Part B of the NefIgArd clinical trial, Calliditas' strategy, business plans and focus. The ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...